The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life

Wang, J. L.; Carter, J.; Kiefer, J. R.; Kurumbail, R. G.; Pawlitz, J. L.; Brown, D.; Hartmann, S. J.; Graneto, M. J.; Seibert, K. S.; Talley, J. J. Bioorg. Med. Chem. Lett., submitted for publication

The Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.

Zhang, 1997, J. Pharmacol. Exp. Ther., 283, 1069

Portanova, 1996, J. Exp. Med., 184, 883, 10.1084/jem.184.3.883

Gierse, 2008, Eur. J. Pharmacol., 588, 93, 10.1016/j.ejphar.2008.03.057

Aston, K. W.; Brown, D. L.; Carter, J. S.; Deprow, A. M.; Fletcher, T. R.; Hallinan, E. A.; Hamper, B. C.; Huff, R. M.; Kiefer, J. R., Jr.; Koszyk, F.; Kramer, S. W.; Liao, S.; Limburg, D.; Springer, J. R.; Tsymbalov, S.; Wang, L. J.; Xing, L.; Yu, Y. WO 04087687 A1, 2004.

Picot, 1994, Nature, 367, 243, 10.1038/367243a0

Kurumbail, 1996, Nature, 384, 644, 10.1038/384644a0